33 results
IDSA - Prophylaxis to Prevent First Episode of Opportunistic Disease in HIV-AIDS
 • Pneumocystis pneumonia (PCP)
Opportunistic Disease in HIV-AIDS ... encephalitis • Mycobacterium ... • Disseminated Mycobacterium ... Opportunistic #Infections #OIs ... IDSA #management #pharmacology
IDSA - Prophylaxis to Prevent First Episode of Opportunistic Disease in HIV-AIDS
 • Pneumocystis pneumonia (PCP)
Opportunistic Disease in HIV-AIDS ... encephalitis • Mycobacterium ... • Disseminated Mycobacterium ... Opportunistic #Infections #OIs ... IDSA #management #pharmacology
IDSA Recommendations for Preventing Human Papillomavirus Infections and Cervical Cancer Screening for Women with in HIV-AIDS
Recommendations
Recommendations for Preventing ... Women with in HIV-AIDS ... test) is not recommended ... #Treatment #management ... infections #HIVAIDS #pharmacology
IDSA Recommendations for Preventing and Treating Penicillium marneffei Infections in HIV-AIDS
Preventing 1st Episode of Penicilliosis (Primary
Recommendations for Preventing ... Infections in HIV-AIDS ... Preventing 1st ... #Treatment #management ... infections #HIVAIDS #pharmacology
IDSA Recommendations for Preventing and Treating Chagas Disease (American Trypanosomiasis) in HIV-AIDS
Preventing Clinical Disease
Indication:  Individuals
Trypanosomiasis) in HIV-AIDS ... of this therapy is ... Disease Note: Treatment ... is effective in ... infections #HIVAIDS #pharmacology
IDSA Recommendations for Preventing and Treating Bacterial Enteric Infections in HIV-AIDS
Preventing Bacterial Enteric Illness:
 • Antimicrobial
Infections in HIV-AIDS ... Preventing Bacterial ... illness usually is ... #Treatment #management ... infections #HIVAIDS #pharmacology
IDSA Recommendations for Preventing and Treating HHV-8 Diseases—Kaposi Sarcoma (KS), Primary Effusion Lymphoma (PEL), Multicentric Castleman’s
Disease (MCD) in HIV-AIDS ... initiation of ART is ... recommended for KS treatment ... #Treatment #management ... infections #HIVAIDS #pharmacology
IDSA Recommendations for Treating Visceral and Cutaneous Leishmaniasis in HIV-AIDS
Treating Visceral Leishmaniasis - Preferred Therapy:
 •
Leishmaniasis in HIV-AIDS ... amphotericin B 2–4 mg/kg IV ... Leishmaniasis #Prevention ... #Treatment #management ... infections #HIVAIDS #pharmacology
IDSA Recommendations for Treating Mucosal Candidiasis in HIV-AIDS
Oropharyngeal Candidiasis: Initial Episodes (Duration of Therapy: 7–14 days)
Preferred
Candidiasis in HIV-AIDS ... for effective treatment ... mucosal #IDSA #Prevention ... #Treatment #management ... infections #HIVAIDS #pharmacology
IDSA Recommendations for Preventing and Treating Toxoplasma gondii Encephalitis in HIV-AIDS
Indications for Initiating Primary Prophylaxis:
 •
Recommendations for Preventing ... Encephalitis in HIV-AIDS ... Encephalitis #IDSA #Prevention ... #Treatment #opportunistic ... #pharmacology